You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
又一新股首日暴涨!翰森制药(3690.HK)一度涨超30%市值破千亿
格隆汇 06-14 10:48
格隆汇6月14日丨继中烟香港(6055.HK)上市三日内一度累涨85%后,今日又一新股首日出现暴涨走势。以研发为驱动的中国制药公司翰森制药(3692.HK)今日首日上市,盘中一度涨超30%,市值一度突破千亿港元。现报17.9港元,涨25.5%,暂成交14.6亿港元,最新总市值1024亿港元。
翰森制药是一家中国的原研药企业,主要专注于中枢神经系统疾病、抗肿瘤、抗感染、糖尿病、消化道及心血管治疗领域。上述六大治疗领域合计占于2018年中国药品总销售额的62.5%,增长快于整体中国医药行业。
2019年上半年,翰森制药已经有4款新药上市申请获得批准。同时将于2019年至2020年推出近30款在研药物,包括公司认为具高增长潜力的15种在研药物,其中1.1类创新糖尿病药物聚乙二醇洛塞那肽(GLP-1周制剂)已于19年5月获批上市。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account